AI-powered HART - Transforming diagnostics at Mass General

With the help of Prevencio Inc, Massachusetts General Hospital has taken the next step in Diagnostic AI with HART an AI model based around cardiovascular health and blood. What does this mean for Mass General and the future of AI-driven diagnostics?

Prevencio, Inc., the AI-Powered Cardiac Blood Test Company, in collaboration with Massachusetts General Hospital (MGH), announces a breakthrough in medical diagnostics with their Artificial Intelligence (AI)-driven HART® platform. This revolutionary platform has produced seven highly accurate multiple protein blood tests, presented in 32 peer-reviewed manuscripts and presentations, providing valuable insights for a range of health conditions. Such a system can truly revolutionize Mass General's work with cardiac diseases and more.

AI-Driven HART Platform

Mass General's new HART platform utilizes cutting-edge AI technology and has demonstrated impressive accuracy across a diverse patient population. By using a variety of predictive markers the tests have been generated by HART have been successful in patients with diabetes, chronic kidney disease, hypertension, obesity, coronary heart disease, heart failure, chronic total occlusion (CTO) of the heart arteries, and Kawasaki disease. Remarkably, the HART platform is not limited to cardiac diseases; it shows potential for developing diagnostics for other medical conditions as well.

Out of the various parameters that HART AI looks at there are 2 main parameters it considers

- HART CVE: Assessing Short-to-Intermediate Risk

HART CVE determines a patient's short-to-intermediate risk for a heart attack, stroke, or cardiovascular death. It provides vital information to healthcare providers for effective risk management and preventive strategies. Using a wide array of data points HART CVE plots and predicts impending short-term heart-related risks.

- HART CADhs: Identifying Impending Heart Attack Risk

HART CADhs assesses whether a patient has obstruction of the heart arteries and is at imminent risk of a heart attack. This test aids in timely intervention, potentially preventing life-threatening events. HART CADhs looks at the immediate information to provide clinicians with the latest updates on obstructions to main organs like the heart.

Groundbreaking Research and Validation a Win for Mass General

Researchers from Massachusetts General Hospital (MGH) collaborated on the development and validation of the AI-driven HART platform. The team tested over 1,250 patients undergoing coronary or peripheral angiography, yielding promising results for the seven algorithmic multiple protein blood tests. Moreover, the collaboration with Prevencio, Inc. on the development of the AI-driven HART platform presents significant benefits for Mass General. As a premier research institution and healthcare provider, MGH gains access to cutting-edge technology that has yielded seven highly accurate multiple protein blood tests, showcasing its commitment to innovation and excellence in patient care. The successful application of the HART platform across a wide range of patients, including those with various cardiovascular conditions and other diseases, expands MGH's capabilities in personalized medicine, enabling tailored treatment plans and improved patient outcomes.

Beyond the heart

The HART platform's potential extends beyond cardiovascular disease and testing. Prevencio has been approached by Seattle Children's Hospital and Research Institute to develop and commercialize a diagnostic for Kawasaki disease. leading cancer centers and global companies are engaging with Prevencio to leverage the HART platform for assessing patient risk, evaluating treatment efficacy, and developing new diagnostics and medical devices.